Thyme Care Secures $125M+, Launches New Oncology Venture
September 15, 2026, 3:32 pm
Thyme Care, a leading oncology management firm, has secured over $125 million in Series E funding. This substantial investment powers its profitable value-based care model. It also establishes Thyme Companies, a new parent entity. This new venture targets critical oncology bottlenecks. Focus areas include biosimilar adoption and clinical trial accrual. Morgan Health led the round. Major strategic and institutional investors participated. These include Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health. The move signals a major shift in cancer care delivery and innovation.
Thyme Care, a national oncology leader, has closed a Series E funding round exceeding $125 million. This significant capital infusion signals robust confidence in its innovative model. The investment propels Thyme Care's existing operations. It also launches a new strategic entity: Thyme Companies. This parent organization aims to dismantle systemic barriers in cancer care.
Morgan Health spearheaded the financing. Strategic healthcare investors also joined. Humana and CVS Health Ventures represent major national payers. Institutional investors include AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. This diverse syndicate underscores broad industry belief in Thyme Care's vision.
Thyme Care already commands a strong position. It manages over $7 billion in annual oncology spend. The company operates profitably. It generates positive free cash flow. Its platform reaches over 10.5 million individuals. Services span all 50 states. This expansive reach demonstrates its proven model.
The company's core offering focuses on value-based oncology navigation. It integrates dedicated care teams. Predictive risk software enhances patient pathways. Community oncology practices are also key partners. This integrated approach reduces healthcare costs. Studies validate a 5% to 10% reduction in total care costs. This outcome resonates with payers and patients alike. It improves care quality. It lowers financial burdens.
The launch of Thyme Companies marks a pivotal expansion. This new parent entity will incubate and scale independent operating businesses. Its mission is clear: address persistent bottlenecks across the oncology journey. These roadblocks often hinder effective treatment and slow innovation.
Initial focus areas for Thyme Companies are critical. One priority involves biosimilar uptake acceleration. Biosimilars offer lower-cost alternatives to expensive biologic drugs. Faster adoption can significantly reduce spend. This benefits commercial and Medicare Advantage plans. Dedicated software and operational pathways will drive this change.
Another key initiative targets decentralized clinical trial accrual. Clinical trials are vital for new drug development. They offer advanced treatment options. Yet, patient enrollment remains a chronic challenge. Thyme Companies plans workflow and data tools. These tools will match community cancer patients with suitable trials. This improves patient access. It accelerates drug development. The first independent business unit under Thyme Companies is slated for launch later this year.
This strategic realignment includes leadership changes. Robin Shah, Thyme Care co-founder, transitions. He will serve as Executive Chairman of Thyme Companies. Shah will oversee corporate strategy. He will incubate new business lines. Dr. Bobby Green, also a co-founder, will collaborate on Thyme Companies' clinical roadmap. Dr. Green continues as President and Chief Medical Officer of Thyme Care. Dr. Brad Diephuis remains Chief Executive Officer of Thyme Care. He leads the core navigation platform. This structure ensures continuity for Thyme Care. It also provides dedicated leadership for new ventures.
The healthcare landscape constantly evolves. Oncology care faces unique pressures. High costs, complex treatments, and access disparities are prevalent. Thyme Care's value-based approach offers a proven solution. Its ability to reduce costs while improving care outcomes is compelling. The expansion into Thyme Companies addresses broader systemic issues.
The market for oncology solutions is immense. The need for efficiency and innovation is paramount. Thyme Care's success demonstrates a clear path forward. Its ability to attract significant investment speaks volumes. Major players recognize its impact. The establishment of Thyme Companies extends this impact. It tackles new frontiers in cancer treatment delivery.
This move reinforces a broader industry trend. Healthcare is shifting towards proactive, integrated models. Companies are addressing patient needs holistically. They are leveraging technology. They are optimizing financial accountability. Thyme Care stands at the forefront of this transformation.
The new structure provides agility. Thyme Companies can pursue distinct market opportunities. These might be too niche for the core Thyme Care platform. It allows specialized teams to focus on specific challenges. This fosters rapid innovation. It creates a robust portfolio of oncology solutions.
Thyme Care’s journey exemplifies a commitment to patient-first care. Its model simplifies the cancer journey for individuals. It reduces their financial burden. The launch of Thyme Companies amplifies this commitment. It seeks to build a more efficient, equitable oncology system. This latest funding round solidifies its position. It empowers its ambitious future. Thyme Care continues to reshape cancer care for millions.
Thyme Care, a national oncology leader, has closed a Series E funding round exceeding $125 million. This significant capital infusion signals robust confidence in its innovative model. The investment propels Thyme Care's existing operations. It also launches a new strategic entity: Thyme Companies. This parent organization aims to dismantle systemic barriers in cancer care.
Morgan Health spearheaded the financing. Strategic healthcare investors also joined. Humana and CVS Health Ventures represent major national payers. Institutional investors include AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. This diverse syndicate underscores broad industry belief in Thyme Care's vision.
Thyme Care already commands a strong position. It manages over $7 billion in annual oncology spend. The company operates profitably. It generates positive free cash flow. Its platform reaches over 10.5 million individuals. Services span all 50 states. This expansive reach demonstrates its proven model.
The company's core offering focuses on value-based oncology navigation. It integrates dedicated care teams. Predictive risk software enhances patient pathways. Community oncology practices are also key partners. This integrated approach reduces healthcare costs. Studies validate a 5% to 10% reduction in total care costs. This outcome resonates with payers and patients alike. It improves care quality. It lowers financial burdens.
The launch of Thyme Companies marks a pivotal expansion. This new parent entity will incubate and scale independent operating businesses. Its mission is clear: address persistent bottlenecks across the oncology journey. These roadblocks often hinder effective treatment and slow innovation.
Initial focus areas for Thyme Companies are critical. One priority involves biosimilar uptake acceleration. Biosimilars offer lower-cost alternatives to expensive biologic drugs. Faster adoption can significantly reduce spend. This benefits commercial and Medicare Advantage plans. Dedicated software and operational pathways will drive this change.
Another key initiative targets decentralized clinical trial accrual. Clinical trials are vital for new drug development. They offer advanced treatment options. Yet, patient enrollment remains a chronic challenge. Thyme Companies plans workflow and data tools. These tools will match community cancer patients with suitable trials. This improves patient access. It accelerates drug development. The first independent business unit under Thyme Companies is slated for launch later this year.
This strategic realignment includes leadership changes. Robin Shah, Thyme Care co-founder, transitions. He will serve as Executive Chairman of Thyme Companies. Shah will oversee corporate strategy. He will incubate new business lines. Dr. Bobby Green, also a co-founder, will collaborate on Thyme Companies' clinical roadmap. Dr. Green continues as President and Chief Medical Officer of Thyme Care. Dr. Brad Diephuis remains Chief Executive Officer of Thyme Care. He leads the core navigation platform. This structure ensures continuity for Thyme Care. It also provides dedicated leadership for new ventures.
The healthcare landscape constantly evolves. Oncology care faces unique pressures. High costs, complex treatments, and access disparities are prevalent. Thyme Care's value-based approach offers a proven solution. Its ability to reduce costs while improving care outcomes is compelling. The expansion into Thyme Companies addresses broader systemic issues.
The market for oncology solutions is immense. The need for efficiency and innovation is paramount. Thyme Care's success demonstrates a clear path forward. Its ability to attract significant investment speaks volumes. Major players recognize its impact. The establishment of Thyme Companies extends this impact. It tackles new frontiers in cancer treatment delivery.
This move reinforces a broader industry trend. Healthcare is shifting towards proactive, integrated models. Companies are addressing patient needs holistically. They are leveraging technology. They are optimizing financial accountability. Thyme Care stands at the forefront of this transformation.
The new structure provides agility. Thyme Companies can pursue distinct market opportunities. These might be too niche for the core Thyme Care platform. It allows specialized teams to focus on specific challenges. This fosters rapid innovation. It creates a robust portfolio of oncology solutions.
Thyme Care’s journey exemplifies a commitment to patient-first care. Its model simplifies the cancer journey for individuals. It reduces their financial burden. The launch of Thyme Companies amplifies this commitment. It seeks to build a more efficient, equitable oncology system. This latest funding round solidifies its position. It empowers its ambitious future. Thyme Care continues to reshape cancer care for millions.